Using aerosolized therapy to treat hemoglobin toxicity in hemolytic diseases
Aerosolized therapy for hemoglobin toxicity in the treatment of hemolytic diseases
This study is exploring a new way to help people with hemolytic diseases by using a special inhaled treatment that could reduce harmful effects from broken down red blood cells, making it a gentler option than standard therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-10982510 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treating hemolytic diseases by delivering aerosolized therapy aimed at reducing hemoglobin toxicity. The study focuses on how this method can effectively target and alleviate the toxic effects associated with hemolysis, potentially improving patient outcomes. Patients may receive this therapy through inhalation, which could offer a less invasive alternative to traditional treatments. The research aims to evaluate the safety and efficacy of this approach in a clinical setting.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with hemolytic diseases who experience complications related to hemoglobin toxicity.
Not a fit: Patients who do not have hemolytic diseases or those whose conditions are not related to hemoglobin toxicity may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option that reduces hemoglobin toxicity and improves the quality of life for patients with hemolytic diseases.
How similar studies have performed: While aerosolized therapies have been explored in other contexts, this specific application for hemoglobin toxicity in hemolytic diseases is relatively novel and has not been extensively tested.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Irwin, David Charles — University of Colorado Denver
- Study coordinator: Irwin, David Charles
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.